HCRU findings
基于日本全国索赔数据，分析复发/难治性弥漫性大B细胞淋巴瘤患者接受自体干细胞移植后的医疗费用与资源利用情况。
基本信息
资源简介
HCRU findings
【数据集背景】
本数据集源站标题为《HCRU findings.》。源站首次发布：2025-02-06。
【数据内容】
源站原始描述：Diffuse large B-cell lymphoma (DLBCL) is the most prevalent non-Hodgkin lymphoma, with increasing incidence, in Japan. It is associated with substantial economic burden and relatively poor survival outcomes for relapsed/ refractory (r/r) DLBCL patients. Despite its association with economic burden and the relatively limited number of eligible patients in Japan as reported in previous real-world studies, Japanese clinical guidelines recommend stem-cell transplantation (SCT) for transplant-eligibl…
【数据结构与技术规格】
文件数 1 个，合计 5.63 KB。Table 3.xls：application/vnd.ms-excel，5.63 KB。数据集 DOI：10.1371/journal.pone.0317439.t003。
【主题与分类】
源站学科分类：Medicine、Cell Biology、Immunology、Biological Sciences not elsewhere classified、Cancer、Science Policy。主题标签：structural equation modeling、structural equation model、statistically significant factors、month &# 160、future innovative therapies、back &# 160、44 [$ 42、healthcare resource use、frequent subsequent therapy、received sct met。
【适用方向】
结构化表格数据可直接用于统计建模、特征工程与队列分析。
【获取与许可】
源站页面：https://plos.figshare.com/articles/dataset/HCRU_findings_/28364648
使用许可：CC BY 4.0（https://creativecommons.org/licenses/by/4.0/）。
规范引用：Tsutsué, Saaya; Makita, Shinichi; Asou, Hiroya; Wada, Shingo; Lee, Wen Shi; Ainiwaer, Dilinuer; et al. (2025). HCRU findings.. PLOS ONE. Dataset
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载，适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档，适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务（收技术服务费，非数据销售）
暂未开放当前数据集主要来源为 Kaggle 公开托管，完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取（Figshare）
- 源站标题：HCRU findings.
- DOI：10.1371/journal.pone.0317439.t003
- 发布日期：2025-02-06
- 文件数：1 个
- 文件总体积：5.63 KB
- 源站页面：https://plos.figshare.com/articles/dataset/HCRU_findings_/28364648
命令行下载
curl -L -o "Table 3.xls" "https://ndownloader.figshare.com/files/52188428"
文件清单
Table 3.xls（5.63 KB）
文件总体积 5.63 KB（源站 API 实测）。
数据说明
Diffuse large B-cell lymphoma (DLBCL) is the most prevalent non-Hodgkin lymphoma, with increasing incidence, in Japan. It is associated with substantial economic burden and relatively poor survival outcomes for relapsed/ refractory (r/r) DLBCL patients. Despite its association with economic burden and the relatively limited number of eligible patients in Japan as reported in previous real-world studies, Japanese clinical guidelines recommend stem-cell transplantation (SCT) for transplant-eligible r/r DLBCL patients. This is the first study to elucidate the total healthcare cost, associated cost drivers and healthcare resource use of SCT among patients with r/r DLBCL in a nationwide setting. The study design included a follow-up period of up to 24 months with subsequent lines of therapies using retrospective nationwide claims data from the Medical Data Vision Co., Ltd. Health Insurance Association from April 2012 to August 2022. Included patients had a confirmed diagnosis of DLBCL, received allogeneic SCT (allo-SCT) or autologous SCT (ASCT) after the first DLBCL diagnosis, and received high-dose chemotherapy during the 6-month look-back period. The results confirmed that no patients had allo-SCT, hence only ASCT was included in the analysis. Structural equation modeling was used to identify potential total healthcare cost drivers by evaluating direct, indirect, and total effects and provide a benchmark reference for future innovative therapies. A total of 108 patients (3.8%) among all DLBCL patients who received SCT met the eligibility criteria and were considered ASCT patients; majority of which were males (n = 63, 58.33%), with a mean [median] (SD) age of 52.04 [55] (9.88) years. A total of 15 patients (13.89%) received subsequent therapies. The most frequent subsequent therapy was GDP-based with or without rituximab (n = 8, 7.41%). The mean [median] (SD) number of follow-up hospitalizations on or after SCT-related hospitalizations was 1.66 [1] (1.36), with a mean [median] (SD) length of hospital stay being 36.88 [34] (12.95) days. The total mean [median] (SD) healthcare cost after adjustment incurred per patient per year during follow-up was $79,052.44 [$42,72
许可
CC BY 4.0
引用
学术使用请引用 DOI 10.1371/journal.pone.0317439.t003（source: https://plos.figshare.com/articles/dataset/HCRU_findings_/28364648）。
数据缺失？
依托陕西、四川两大基地，我们与超过十家三甲医院建立直接合作关系，覆盖合规授权、采集治理、专业标注、数据交付的全流程，为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务？立即联系我们获取专业方案。
